NDLI: Role of SH3GLB1 in the regulation of CD133 expression in GBM cells

Content Provider	Springer Nature : BioMed Central
Author	Chien, Chia-Hung Lai, Chien-Cheng Chuang, Jian-Ying Chu, Jui-Mei Liu, Chan-Chuan Chang, Kwang-Yu
Abstract	Background Glioblastoma (GBM), a malignant brain tumor, has poor survival outcomes due to recurrence or drug resistance. We found that SH3GLB1 is a crucial factor for cells to evade temozolomide (TMZ) cytotoxicity through autophagy-mediated oxidative phosphorylation, which is associated with CD133 levels. Therefore, we propose that SH3GLB1 participate in the impact on tumor-initiating cells (TICs). Methods The parental, the derived resistant cell lines and their CD133+ cells were used, and the levels of the proteins were compared by western blotting. Then RNA interference was applied to observe the effects of the target protein on TIC-related features. Finally, in vitro transcription assays were used to validate the association between SH3GLB1 and CD133. Results The CD133+ cells from resistant cells with enhanced SH3GLB1 levels more easily survived cytotoxic treatment than those from the parental cells. Inhibition of SH3GLB1 attenuated frequency and size of spheroid formation, and the levels of CD133 and histone 4 lysine 5 (H4K5) acetylation can be simultaneously regulated by SH3GLB1 modification. The H4K5 acetylation of the CD133 promoter was later suggested to be the mediating mechanism of SH3GLB1. Conclusions These data indicate that SH3GLB1 can regulate CD133 expression, suggesting that the protein plays a crucial role in TICs. Our findings on the effects of SH3GLB1 on the cells will help explain tumor resistance formation.
Related Links	https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-023-11211-8.pdf
Ending Page	8
Page Count	8
Starting Page	1
File Format	HTM / HTML
ISSN	14712407
DOI	10.1186/s12885-023-11211-8
Journal	BMC Cancer
Issue Number	1
Volume Number	23
Language	English
Publisher	BioMed Central
Publisher Date	2023-07-31
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Surgical Oncology Health Promotion and Disease Prevention Biomedicine Medicine Public Health SH3GLB Resistance TICs CD133 Histone acetylation Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology Genetics
Journal Impact Factor	3.4/2023
5-Year Journal Impact Factor	3.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

CD133 antigen expression in ovarian cancer

Prognostic role of CD133 expression in colorectal cancer: a meta-analysis

Systematic analysis of histone acetylation regulators across human cancers

CD133 expression in chemo-resistant Ewing sarcoma cells

Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells

DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells

CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy

Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal

RPS6KA1 is a histone acetylation-related oncoprotein in acute myeloid leukemia which is targeted by afzelin

Role of SH3GLB1 in the regulation of CD133 expression in GBM cells

Similar Documents

CD133 antigen expression in ovarian cancer

Prognostic role of CD133 expression in colorectal cancer: a meta-analysis

Systematic analysis of histone acetylation regulators across human cancers

CD133 expression in chemo-resistant Ewing sarcoma cells

Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells

DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells

CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy

Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal

RPS6KA1 is a histone acetylation-related oncoprotein in acute myeloid leukemia which is targeted by afzelin

Role of SH3GLB1 in the regulation of CD133 expression in GBM cells